Related Experiment Video
Updated: Jun 16, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options
Sven G Meuth1, Christoph Kleinschnitz
1Department of Neurology, University of Wuerzburg, Wuerzburg, Germany.
European Neurology
|February 13, 2010
Summary
Multifocal motor neuropathy (MMN) causes progressive limb weakness due to immune system attacks. High-dose intravenous immunoglobulin therapy is effective, but optimal long-term treatment requires further research.
Area of Science:
- Neurology
- Immunology
- Clinical Neuroscience
Background:
- Multifocal motor neuropathy (MMN) is an immune-mediated disorder causing progressive limb weakness.
- It is characterized by asymmetrical weakness, predominantly in upper extremities, and conduction blocks.
- Distinguishing MMN from motor neuron disease and other neuropathies is crucial.
Purpose of the Study:
- To review the clinical presentation and pathophysiology of MMN.
- To focus on the molecular and electrophysiological basis of conduction blocks.
- To highlight current and potential future therapies for MMN.
Main Methods:
- Literature review of clinical studies and research on MMN.
- Analysis of diagnostic criteria, including electrophysiology and serology.
- Evaluation of therapeutic strategies and outcomes.
Main Results:
- MMN presents with asymmetrical, progressive weakness and conduction blocks.
- High-titer anti-GM1 antibodies are a key diagnostic marker.
- Intravenous immunoglobulin (IVIg) is the primary treatment, while corticosteroids and plasma exchange are less effective.
Conclusions:
- MMN pathophysiology is increasingly understood, particularly regarding conduction blocks.
- IVIg is the established first-line treatment for MMN.
- Further research is needed to clarify long-term management and novel therapeutic options.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...